Identification of HIF1A as a therapeutic target during SARS-CoV-2-associated lung injury. - Bobrow B; Luber SD; Potnuru P; Figarella K; Kim J; Wang Y; Bang IH; Robinson D; Sergot PB; Burke SK; Mills T; de Dios C; et al. (JCI insight, 2025)